Viewing nowLisemax Tablet 150 mg (Lisedronic Acid Sodium 2.5 Hydrate)
Risedronate Sodium 2.5 Hydrate 172.1386mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

MFDS item code 201004224 · Approved 2010.06.28 · Insurance code 644307910
Treatment and prevention of osteoporosis in postmenopausal women
This medication is used to treat and prevent osteoporosis in postmenopausal women.
1. Adults : Administer risedronate sodium 150 mg orally once a month. 2. Elderly patients : No dosage adjustment is necessary in elderly patients (over 60 years of age), since the bioavailability and pharmacodynamics of this medicine are similar to those in younger people. 4. Patients with renal impairment : No dosage adjustment is necessary in patients with creatinine clearance of 30 mL/min or higher. This medicine is contraindicated in patients with severe renal impairment and creatinine clearance below 30 mL/min. ○ Food interferes with absorption of this medicine. To ensure adequate absorption, take it at least 30 minutes before the first food or beverage other than water of the day. To facilitate passage of this medicine into the stomach and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ∼ 230 mL). Taking it with other beverages, including mineral water, may reduce absorption. Do not chew or suck this medicine because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking the medicine. ○ If a patient forgets to take the medicine on the scheduled day, take it as follows. - If the next scheduled dose is at least 7 days away, take 1 tablet the next morning after remembering. Take the next dose on the originally scheduled day. Do not take more than 1 tablet of this medicine within 7 days. - If the next scheduled dose is within 7 days, wait until the originally scheduled day and take 1 tablet.
3. Children : Safety and efficacy have not been established in children under 18 years of age.
This drug is an oral bisphosphonate, primarily used for the treatment of osteoporosis. It may irritate the upper gastrointestinal mucosa upon administration; therefore, patients with upper gastrointestinal diseases such as Barrett's esophagus, dysphagia, esophageal diseases, gastritis, duodenitis, and ulcers should exercise caution. It is essential to follow the dosage instructions strictly, and after taking the medication, do not lie down for at least 30 minutes, and take it with a sufficient amount of water to reduce the risk of esophageal irritation. If symptoms such as esophagitis, esophageal ulcers, or esophageal erosion appear, immediately stop taking the medication and consult a physician. This drug should not be administered to specific patients, including those with esophageal motility disorders, hypocalcemia, pregnant or nursing women, and those with severe renal impairment. Additionally, patients with genetic issues such as lactose intolerance should not take this drug due to lactose content. It is vital to take sufficient calcium and vitamin D during treatment, and if hypocalcemia or parathyroid dysfunction is present, treatment must occur before use. Similar to other drugs in the same class, rare serious side effects such as osteonecrosis of the jaw, atypical femoral fractures, and osteonecrosis of the external auditory canal have been reported; therefore, if such symptoms occur, immediate consultation with healthcare personnel is necessary. Antacids containing drugs such as calcium, magnesium, iron, and aluminum should not be taken simultaneously as they may interfere with absorption; therefore, the timing of these medications must be adjusted. Pregnant women or women who may become pregnant and nursing mothers should not use this drug, as it may affect the fetus during pregnancy, requiring caution. The safety and efficacy in children have not been established, and the elderly can use it without significant differences, but careful observation is necessary. In case of overdose, symptoms of hypocalcemia may appear, requiring appropriate treatment such as administering ionized calcium, and gastric lavage should be considered. Keep this medication out of reach of children, and avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to avoid exposure to air, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the drug's effectiveness for a longer time.
Blue oval film-coated tablet
1 tablet (1 tablet/PTPX1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRisedronate Sodium 2.5 Hydrate 172.1386mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Austin Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Nexpam Korea Co., Ltd.

Risedronate Sodium 2.5 Hydrate 35mg
Tablet · Prescription medication
Hyutecs Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.2mg
Tablet · Prescription medication
Celix Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Myeongmun Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.